Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.69, missing the estimate of USD -0.6514.

EBIT: As of FY2026 Q2, the actual value is USD -45.56 M.

Cash, Cash Equivalents and Marketable Securities

As of June 30, 2026, Tyra Biosciences, Inc. reported cash, cash equivalents, and marketable securities totaling $353.9 million, which is expected to provide a cash runway into the second half of 2028. This compares to $256.0 million as of December 31, 2025. As of June 30, 2026, cash and cash equivalents were $73,835 thousand and marketable securities were $280,109 thousand.

Research and Development (R&D) Expenses

R&D expenses for the three months ended June 30, 2026, were $39.2 million, an increase from $24.3 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $72.7 million, up from $49.3 million for the same period in 2025. The increase was primarily due to development activities for oral dabogratinib, supporting the SURF303, SURF302, and BEACH301 clinical trials, along with increases in personnel expenses and facilities costs.

General and Administrative (G&A) Expenses

G&A expenses for the three months ended June 30, 2026, were $9.8 million, compared to $7.1 million for the same period in 2025. For the six months ended June 30, 2026, G&A expenses were $18.3 million, an increase from $14.0 million for the same period in 2025. This rise was mainly driven by higher compensation and other personnel costs due to headcount growth.

Total Operating Expenses

Total operating expenses for the three months ended June 30, 2026, were $49.0 million, increasing from $31.5 million for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $91.0 million, compared to $63.3 million for the same period in 2025.

Loss from Operations

Loss from operations for the three months ended June 30, 2026, was - $49.0 million, compared to - $31.5 million for the same period in 2025. For the six months ended June 30, 2026, the loss from operations was - $91.0 million, compared to - $63.3 million for the same period in 2025.

Other Income (Interest and other income, net)

Interest and other income, net, for the three months ended June 30, 2026, was $3.4 million, slightly up from $3.4 million for the same period in 2025. For the six months ended June 30, 2026, this income was $6.1 million, compared to $7.1 million for the same period in 2025.

Net Loss

Net loss for the second quarter of 2026 was - $45.6 million, compared to - $28.1 million for the same period in 2025. For the six months ended June 30, 2026, the net loss was - $84.9 million, compared to - $56.2 million for the same period in 2025.

Comprehensive Loss

Comprehensive loss for the three months ended June 30, 2026, was - $46.2 million, compared to - $28.4 million for the same period in 2025. For the six months ended June 30, 2026, the comprehensive loss was - $85.8 million, compared to - $56.6 million for the same period in 2025.

Unique Financial Metrics

In August 2026, Tyra Biosciences, Inc. amended its sales agreement with TD Securities (USA) LLC, allowing the company to sell an additional $250.0 million of its common stock in at-the-market offerings.

Outlook / Guidance

Tyra Biosciences, Inc. anticipates initial Phase 2 data from the SURF302 study in September 2026 and initial results from the SURF303 study in 2027. Initial safety sentinel cohort data from the BEACH301 study is expected by the end of Q1 2027. The company projects its current cash, cash equivalents, and marketable securities will fund operations into the second half of 2028.